bone metastasis in solid tumors epidemiology forecast us insight

DelveInsight’s ‘Bone Metastasis in Solid Tumors – Epidemiology Forecast—2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Bone Metastasis in Solid Tumors in the United States.Bone Metastasis in Solid Tumors (Bone Metastasis in Solid Tumors): Disease Understanding

Geography Covered

• The United States

Study Period: 2021-2034

Bone Metastasis in Solid Tumors Overview

Metastases are defined as the process by which cancer cells leave the primary tumor, migrate, and implant into a distant organ, where they proliferate and form new tumor foci. Bone is one of the most common sites of distant metastases. Cancers most likely to spread to the bones are breast, prostate, lung, kidney, thyroid, multiple myeloma, and lymphoma. Almost 50–70% of those with advanced breast and prostate cancer have bone involvement. It causes significant morbidity and reduced quality of life.

 

The development of bone metastases can be considered in several stages: colonization, quiescence, progression, either locally leading to overt metastasis in bone or dissemination to another site. Pain is the most common symptom of bone metastases. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, the need for bone irradiation or need for bone surgery, and hypercalcemia.

 

According to the primary mechanism of interference with normal bone remodeling, bone metastasis is classified as osteolytic, osteoblastic, or mixed lesions. When bone resorption mediated by osteoclasts dominates, as in many patients with lung cancer or multiple myeloma, focal bone destruction occurs, resulting in what is often described as ‘punched out’ lytic lesions. Conversely, in bone metastases characterized by increased osteoblast activity, such as in patients with prostate cancer, the metastatic bone appears as dense osteosclerotic lesions. Although one component may seem to predominate, both processes are usually accelerated within the bone metastasis, resulting in ‘mixed’ lesions in which both lytic and sclerotic components are visible.

 

The diagnosis is based on signs, symptoms, and imaging; it has major clinical consequences for the patient concerned and, therefore, a timely and definite diagnosis is crucial. The standard of care imaging methods for bone metastases detection includes plain X-ray, computed tomography (CT) scan, and radionuclide bone scintigraphy.

 

Although treatment of bone metastases is rarely curative, disease control is often possible for many years by using systemic anticancer treatments on a background of multidisciplinary supportive care. This care includes bone-targeted agents such as bisphosphonates or denosumab to inhibit tumor-associated osteolysis and prevent skeletal morbidity and the use of appropriate local treatments such as radiation therapy, orthopedic surgery, and specialist palliative care to minimize the impact of metastatic bone disease on physical functioning.

 

Bone metastases have an important impact on a patient’s quality of life so, new strategies are necessary to prevent skeletal disease and palliate established skeletal events. In addition, more studies are necessary to elucidate the interaction between the tumor cell and bone microenvironment to reach new therapeutic interventions.

Bone Metastasis in Solid Tumors: Epidemiology

The Bone Metastasis in Solid Tumors epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Bone Metastasis in Solid Tumors epidemiology segmented as the Diagnosed Prevalent Cases of Bone Metastasis in Solid Tumors and Cases of Bone Metastasis by Solid Tumor type. The report includes the prevalent scenario of Bone Metastasis in Solid Tumors in the United States from 2021 to 2034.

Country-Wise Bone Metastasis in Solid Tumors Epidemiology

The epidemiology segment also provides the Bone Metastasis in Solid Tumors epidemiology data and findings in the United States.

 

The total diagnosed prevalent population of Bone Metastasis in Solid Tumors in the United States was estimated to be 369,356 cases in 2020.

Scope of the Report

• Bone Metastasis in Solid Tumors report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Bone Metastasis in Solid Tumors Epidemiology Report and Model provide an overview of the risk factors and trends of Bone Metastasis in Solid Tumors in the United States.
• The report provides insight into the historical and forecasted patient pool of Bone Metastasis in Solid Tumors in the United States.
• The report helps recognize the growth opportunities in the United States concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Bone Metastasis in Solid Tumors.
• The report provides the segmentation of the Bone Metastasis in Solid Tumors epidemiology by Diagnosed Prevalent cases of Bone Metastasis in Solid Tumors in the United States.
• The report provides the segmentation of the Bone Metastasis in Solid Tumors epidemiology by Cases of Bone Metastasis by Solid Tumor type in the United States.

Report Highlights

• 10-year Forecast of Bone Metastasis in Solid Tumors epidemiology
• US Coverage
• Diagnosed Prevalent Cases of Bone Metastasis in Solid Tumors
• Cases of Bone Metastasis by Solid Tumor type

KOL Views

We interview KOLs and obtain SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the United States for the patient population pertaining to Bone Metastasis in Solid Tumors?
• What are the key findings pertaining to the Bone Metastasis in Solid Tumors epidemiology in the United States?
• What would be the total number of patients with Bone Metastasis in Solid Tumors in the United States during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow in the United States during the forecast period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of Bone Metastasis in Solid Tumors?
• What are the currently available treatments for Bone Metastasis in Solid Tumors?

Reasons to buy

Bone Metastasis in Solid Tumors Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the United States Bone Metastasis in the Solid Tumors market
• Quantify patient populations in the global Bone Metastasis in Solid Tumors market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Bone Metastasis in Solid Tumors therapeutics in each of the markets covered.
• Understand the magnitude of the Bone Metastasis in the Solid Tumors population by its Diagnosed Prevalent cases.
• Understand the magnitude of the Bone Metastasis in the Solid Tumors population by its Cases of Bone Metastasis by Solid Tumor type
• The Bone Metastasis in Solid Tumors epidemiology report and model was written and developed by Masters and Ph.D. level epidemiologists
• The Bone Metastasis in Solid Tumors Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population